Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (2588)	2/28/2012 10:36:59 AM
From: richardred	Respond to of 7239

Bayer Could Finance ‘Significant’ Acquisition, CFO Says By Naomi Kresge Feb 28, 2012 7:03 AM ET Bayer AG (BAYN) could finance a “significant” acquisition using a combination of debt, equity and its portfolio assets, Chief Financial Officer Werner Baumann said in an interview today. The German drug and chemical maker would only sell one of its three units “on the merits of its own strategic assessment,” not to finance a deal, Baumann said. “You will not find us in a situation where we say we want to buy this, therefore we have to sell that. We always look at the intrinsic appeal of a business inside of its industry.” Baumann declined to comment on the animal-health unit that Pfizer Inc. (PFE) plans to divest. Bayer doesn’t have a goal in terms of the size of acquisitions it hopes to do, he said. To contact the editor responsible for this story: Naomi Kresge at nkresge@bloomberg.net bloomberg.com

To: richardred who wrote (2588)	4/25/2012 12:09:01 PM
From: richardred	Read Replies (1) \| Respond to of 7239

Bayer eyes multi-billion euro acquisition -sources >snip In late March, Bayer Chief Executive Marijn Dekkers said: "Every company of our size is looking for acquisition opportunities. You have to do it to remain competitive." He has said his M&A focus would be on the healthcare and the genetically-modified seeds industries. CEO Dekkers, who has a track record of big M&A deals like the creation of lab equipment maker Thermo Fisher, joined Bayer in 2011 and investors have been scouring for clues ever since as to where he plans to take the 148 year-old German drugmaker. "Dekkers is keen to do something and it could happen within the next couple of days," one of the sources said. reuters.com